Summary
Murine colon 26 carcinoma growing at either subcutaneous (s.c.) or intramuscular (i.m.) inoculation sites causes cachexia in mice. Such animals show extensive loss of body weight, wasting of the muscle and adipose tissues, hypoglycaemia, and hypercalcaemia, even when the tumour weight comprises only about 1.9% of carcass weight. In contrast, the same tumour when inoculated into the liver does not cause any sign of tumour-related cachexia even when the tumour becomes much larger (6.6% of carcass weight). Interleukin 6 (IL-6), a mediator associated with cachexia in this tumour model, is detected at high levels both in the tumour tissues and in the circulating blood of mice bearing colon 26 tumour at the s.c. inoculation site. In contrast, only minute levels of IL-6 are detected in the tumour grown in the liver. The colon 26 tumour grown in the liver does not lose its ability to cause cachexia, because the tumour when re-inoculated s.c. is able to cause extensive weight loss and produce IL-6 as did the original colon 26 cell line. Histological studies revealed differences in the composition of tumour tissues: the tumours grown in the subcutis consist of many polygonal tumour cells, extended-intercellular space, and high vascular density, whereas those grown in the liver consist of spindle-shaped tumour cells. Thus, the environment where tumour cells grow would be a critical factor in determining the cachectic phenotype of cancer cells, including their ability to produce IL-6.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arend, W. P., Joslin, F. G. & Massoni, R. J. (1985). Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol 134: 3868–3875.
Eda, H., Tanaka, Y. & Ishitsuka, H. (1991). 5´-Deoxy-5-fluorouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice. Cancer Chemother Pharmacol 29: 1–6.
Fiers, W. (1991). Tumour necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Lett 285: 199–212.
Fujimoto-Ouchi, K., Tamura, S., Mori, K., Tanaka, Y. & Ishitsuka, H. (1995). Establishment and characterization of cachexia inducing and non-inducing clones of murine colon 26 carcinoma. Int J Cancer 61: 522–528.
Gelin, J., Moldawer, L. L., Lonnroth, C., Sherry, B., Chizonite, R. & Lundholm, K. (1991). Role of endogenous tumour necrosis factor a and interleukin 1 for experimental tumour growth and the development of cancer cachexia. Cancer Res 51: 415–421.
Gitelman, H. J. (1967). An improved automated procedure for the determination of calcium in biological specimens. Anal Biochem 18: 521–531.
Hsu, S. M., Raine, L. & Fanger, H. (1981). Use of avidin-biotin-peroxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577–580.
Matthys, P., Dijkmans, R., Proost, P., Van Damme, J., Heremans, H., Sobis, H. & Billiau, A. (1991a). Severe cachexia in mice inoculated with interferon-γ-producing tumour cells. Int J Cancer 49: 77–82.
Matthys, P., Heremans, H., Opdenakker, G. & Billiau, A. (1991b). Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer 27: 182–187.
Moldawer, L. L., Georgieff, M. & Lundholm, K. (1987). Interleukin1, tumour necrosis factor-α (cachectin) and the pathogenesis of cancer cachexia. Clin Physiol 7: 263–274.
Mori, M., Yamaguchi, K., Honda, S., Nagasaki, K., Ueda, M., Abe, O. & Abe, K. (1991). Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 51: 6656–6659.
Nakajima, M., Morikawa, K., Fabra, A., Bucana, C. D. & Fidler, I. J. (1990). Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 82: 1890–1898.
Oliff, A., Defeo-Jones, D., Boyer, M., Martinez, D., Kiefer, D., Vuocolo, G., Wolfe, A. & Socher, S. H. (1987). Tumour secreting human TNF/cachectin induce cachexia in mice. Cell 50: 555–563.
Steinkasserer, A., Estaller, C., Weiss, E. H. & Sim, R. B. (1992). Human interleukin-1 receptor antagonist is expressed in liver. FEBS Lett 310: 60–62.
Stovroff, M. C., Fraker, D. L., Swedenborg, J. A. & Norton, J. A. (1988). Cachectin/tumour necrosis factor-α possible mediator of cancer cachexia in the rat. Cancer Res 48: 4567–4572.
Strassmann, G., Fong, M., Kenney, J. S. & Jacob, C. O. (1992a). Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 1681–1684.
Strassmann, G., Jacob, C. O., Evans, R., Beall, D. & Fong, M. (1992b). Mechanisms of experimental cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol 148: 3674–3678.
Strassmann, G., Masui, Y., Chizzonite, R. & Fong, M. (1993). Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumour. J Immunol 150: 2341–2345.
Tamura, S., Fujimoto, K., Mori, K., Endo, M., Matsumoto, T., Eda, H., Tanaka, Y., Ishitsuka, H., Tokita, H. & Yamaguchi, K. (1995). Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res 1: 1353–1358.
Tanaka, Y., Eda, H., Tanaka, T., Udagawa, T., Ishikawa, T., Horii, I., Ishitsuka, H., Kataoka, T. & Taguchi, T. (1990). Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 50: 2290–2295.
Tracey, K. J., Wei, H., Manogue, K. R., Fong, Y., Hesse, D. G., Nguyen, H. T., Kuo, G. C., Beutler, B., Cotran, R. S., Cerami, A. & Lowry, S. F. (1988). Cachectin/tumour necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 167: 1211–1227.
Vidal-Vanaclocha, F., Glaves, D., Barbera-Guillem, E. & Weiss, L. (1991). Quantitative microscopy of mouse colon 26 cells growing in different metastatic sites. Br J Cancer 63: 748–752.
Yoneda, T., Alsina, M. A., Chavez, J. B., Bonewald, L., Nishimura, R. & Mundy, G. R. (1991). Evidence that tumour necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumour in nude mice. J Clin Invest 87: 977–985.
Yoneda, T., Nakai, M., Moriyama, K., Scott, L., Ida, N., Kunitomo, T. & Mundy, G. R. (1993). Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res 53: 737–740.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Matsumoto, T., Fujimoto-Ouchi, K., Tamura, S. et al. Tumour inoculation site-dependent induction of cachexia in mice bearing colon 26 carcinoma. Br J Cancer 79, 764–769 (1999). https://doi.org/10.1038/sj.bjc.6690123
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690123
Keywords
This article is cited by
-
Hypothalamic food intake regulation in a cancer‐cachectic mouse model
Journal of Cachexia, Sarcopenia and Muscle (2014)
-
Preclinical investigation of tolerance and antitumour activity of new fluorodeoxyglucose-coupled chlorambucil alkylating agents
Investigational New Drugs (2011)
-
Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse
BMC Cancer (2010)
-
Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice
British Journal of Cancer (2009)
-
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models
Cancer Chemotherapy and Pharmacology (2007)